Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Yuki Fujiwara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8801-4284; OpenAlex author ID A5083017784. Sources: OpenAlex.

Their work

Papers
27 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 5 papers · 2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 27

  1. Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18426-y↗
  2. ASO Visual Abstract: Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: a Comparative Study with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18603-z↗
  3. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  4. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Co-author DOI 10.1093/bjs/znab092↗
  5. Pancreatic cancer treatment: better, but a long way to go. First author DOI 10.1007/s00595-020-02028-0↗
  6. Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. Co-author DOI 10.21873/anticanres.13952↗
  7. Combination of Distance from Superior Mesenteric Artery and Serum CA19-9 as a Novel Prediction of Local Recurrence in Patients With Pancreatic Cancer Following… First author DOI 10.21873/anticanres.13264↗
  8. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. Co-author DOI 10.1002/ags3.12025↗
  9. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Co-author DOI 10.21873/anticanres.13013↗
  10. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Co-author DOI 10.21873/anticanres.11378↗
  11. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. Co-author DOI 10.1007/s00268-016-3491-4↗
  12. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.034↗
  13. Radical resection of T1 pancreatic adenocarcinoma with a pseudocyst of the tail due to acute obstructive pancreatitis: report of a case. Co-author DOI 10.1186/s40792-016-0268-9↗
  14. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour sit… Co-author DOI 10.3109/00365521.2015.1121515↗
  15. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Co-author DOI 10.1016/j.surg.2015.03.043↗
  16. Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Ca… Co-author DOI 10.9738/intsurg-d-13-00193.1↗
  17. Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. Co-author PMID 26254410↗
  18. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenoc… Co-author PMID 25202109↗
  19. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Co-author DOI 10.1007/s00595-012-0279-5↗
  20. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.01.019↗
  21. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for p… Co-author DOI 10.1016/j.jamcollsurg.2012.09.016↗
  22. Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy. Co-author DOI 10.1097/mpa.0b013e31828cf976↗
  23. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Co-author PMID 24023348↗
  24. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Co-author PMID 23155291↗
  25. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. Co-author DOI 10.1007/s00534-011-0390-9↗
  26. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice. Co-author DOI 10.1016/j.canlet.2011.02.036↗
  27. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic ca… Co-author DOI 10.1097/mpa.0b013e31820b9257↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroaki Shiba · 20 shared papers, 2011–2022 · strength 1.16
  2. Katsuhiko K. Yanaga · 21 shared papers, 2011–2020 · strength 1.13
  3. Koichiro Haruki · 19 shared papers, 2011–2022 · strength 1.12
  4. Richard David Schulick · 4 shared papers, 2020–2026 · strength 0.86
  5. Kenei Furukawa · 16 shared papers, 2011–2022 · strength 0.83
  6. Marco Del Chiaro · 3 shared papers, 2021–2026 · strength 0.68
  7. Yoshihiro Shirai · 9 shared papers, 2014–2022 · strength 0.63
  8. Oskar Franklin · 2 shared papers, 2026 · strength 0.58
  9. Andrii Khomiak · 2 shared papers, 2026 · strength 0.58
  10. Hiroyuki Ishida · 2 shared papers, 2026 · strength 0.58
  11. Tadashi Uwagawa · 12 shared papers, 2011–2018 · strength 0.52
  12. Ryoga Hamura · 4 shared papers, 2018–2022 · strength 0.43
  13. Takeshi Gocho · 5 shared papers, 2012–2022 · strength 0.33
  14. Takashi Horiuchi · 5 shared papers, 2015–2018 · strength 0.31
  15. Taro Sakamoto · 3 shared papers, 2015–2019 · strength 0.23
  16. Robert J. Torphy · 1 shared paper, 2020 · strength 0.19
  17. Fumitake Suzuki · 2 shared papers, 2016–2019 · strength 0.18
  18. Toru Ikegami · 1 shared paper, 2022 · strength 0.13
  19. Shinji Onda · 1 shared paper, 2022 · strength 0.13
  20. Masashi Tsunematsu · 1 shared paper, 2022 · strength 0.13
  21. Shuichi Fujioka · 1 shared paper, 2022 · strength 0.13
  22. Tadashi Uwagawa · 1 shared paper, 2022 · strength 0.13
  23. Alexis Diane Leal · 1 shared paper, 2021 · strength 0.10
  24. Karyn A. Goodman · 1 shared paper, 2021 · strength 0.10
  25. Christopher Hanyoung Lieu · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.